Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, Florida, USA.
J Neurochem. 2013 Dec;127(6):733-8. doi: 10.1111/jnc.12368. Epub 2013 Jul 30.
To explore the hypothesis that alterations in cellular membrane lipids are present at the stage of pre-clinical Alzheimer's disease (AD) (i.e., cognitively normal at death, but with AD neuropathology), we performed targeted shotgun lipidomics of lipid extracts from post-mortem brains of subjects with pre-clinical AD. We found sulfatide levels were significantly lower in subjects with pre-clinical AD compared to those without AD neuropathology. We also found that the level of ethanolamine glycerophospholipid was marginally lower at this stage of AD, whereas changes of the ceramide levels were undetectable with the available samples. These results indicate that cellular membrane defects are present at the earliest stages of AD pathogenesis and also suggest that sulfatide loss is among the earliest events of AD development, while alterations in the levels of ethanolamine glycerophospholipid and ceramide occur relatively later in disease.
为了探索细胞膜脂质改变是否存在于临床前阿尔茨海默病(AD)阶段(即死亡时认知正常,但存在 AD 神经病理学)的假说,我们对临床前 AD 患者死后大脑的脂质提取物进行了靶向 shotgun 脂质组学分析。我们发现,与没有 AD 神经病理学的患者相比,临床前 AD 患者的硫酸脂水平显著降低。我们还发现,在 AD 的这一阶段,乙醇胺甘油磷脂的水平略有降低,而在现有样本中,神经酰胺水平的变化无法检测到。这些结果表明,细胞膜缺陷存在于 AD 发病的最早阶段,并且表明硫酸脂的丢失是 AD 发展的最早事件之一,而乙醇胺甘油磷脂和神经酰胺水平的改变则发生在疾病的相对较晚阶段。